Literature DB >> 29600832

Bullous pemphigoid: Italian guidelines adapted from the EDF/EADV guidelines.

Emanuele Cozzani1, Angelo V Marzano2, Marzia Caproni3, Claudio Feliciani4, Piergiacomo Calzavara-Pinton5.   

Abstract

Bullous pemphigoid is the most common autoimmune subepidermal blistering disease of the skin and mucous membranes. This disease typically affects the elderly and presents with itch and localized or generalized bullous lesions. In up to 20% of affected patients blister may be completely absent, and only excoriations, prurigo-like lesions, eczematous lesions, urticated lesions, and/or infiltrated plaques are observed. The disease is significantly associated with neurological disorders. The morbidity of bullous pemphigoid and its impact on the quality of life are significant. So far, a limited number of national treatment guidelines have been proposed, but no common European consensus has emerged. This guideline for the treatment of bullous pemphigoid has been developed by an Italian group of experts taking in account the Italian legislation and local pharmacological governance. Guidelines are adapted from the original article under the guidance of the European Dermatology Forum (EDF) in collaboration with the European Academy of Dermatology and Venereology (EADV). It summarizes evidence-based and expert-based recommendations (S2 level).

Entities:  

Mesh:

Year:  2018        PMID: 29600832     DOI: 10.23736/S0392-0488.18.06006-6

Source DB:  PubMed          Journal:  G Ital Dermatol Venereol        ISSN: 0392-0488            Impact factor:   2.011


  4 in total

1.  How Do Experts Treat Patients with Bullous Pemphigoid around the World? An International Survey.

Authors:  Marine Guignant; Billal Tedbirt; Dedee F Murrell; Masayuki Amagai; Valeria Aoki; Johannes Bauer; Giuseppe Ciancinni; Donna Culton; Maryam Daneshpazhooh; Dipankar De; Janet Fairley; Russell Hall; Soo-Chan Kim; Neil J Korman; Cezary Kowalewski; Daniel Mimouni; Aikaterini Patsatsi; Vivien Hebert; Marwah Adly Mohamed Saleh; Enno Schmidt; Eli Sprecher; Soner Uzun; Vanessa Venning; Victoria P Werth; Detlef Zillikens; Pascal Joly
Journal:  JID Innov       Date:  2022-04-12

Review 2.  Use of Dupilumab in Bullous Pemphigoid: Where Are We Now?

Authors:  Roberto Russo; Niccolò Capurro; Emanuele Cozzani; Aurora Parodi
Journal:  J Clin Med       Date:  2022-06-12       Impact factor: 4.964

Review 3.  Bullous pemphigoid in diabetic patients treated by gliptins: the other side of the coin.

Authors:  Karim Chouchane; Giovanni Di Zenzo; Dario Pitocco; Laura Calabrese; Clara De Simone
Journal:  J Transl Med       Date:  2021-12-20       Impact factor: 5.531

4.  Bullous pemphigoid triggered by COVID-19 vaccine: Rapid resolution with corticosteroid therapy.

Authors:  Massimo Dell'Antonia; Speranza Anedda; Federica Usai; Laura Atzori; Caterina Ferreli
Journal:  Dermatol Ther       Date:  2021-11-30       Impact factor: 3.858

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.